|
|
|
 |
Search published articles |
 |
|
Showing 8 results for Eshghi
Dr. H. Abolghasemi, M. Amani, A. Jabari, R. Ranjbaran, M.h. Mohammadi, Dr. M. Habibi Roudkenar, A. Ali Balazadeh, A. Hashemi Teir, Dr. N. Amirizadeh, Dr. P. Eshghi,
Volume 6, Issue 3 (Autumn 2009)
Abstract
Abstract Background and Objectives Fibrin sealant (FS) is a plasma derived product and has hemostatic, sealing and healing properties and is frequently used to reduce blood loss during and after surgery. Blood bank autologous fibrin sealants have no risk of transfusion transmitted diseases. The aim of this study was to obtain of thrombin and fibrinogen from FFP and study their in vitro properties for preparation of FS. Materials and Methods Fibrinogen was precipitated by use of protamin sulfate. Fibrinogen concentration was assayed with an enzyme-linked immunosorbent assay and clotting clauss method the effect of temperature on fibrinogen precipitation was also evaluated. Thrombin was prepared by manual method and TPD and its activity was then determined using specific chromogenic substrate spectrophotometric assay. Thrombin stability at different temperature degrees was evaluated and clotting time was measured. Tensile strength and adhesion strength were evaluated with the tensiometry device. Clot lysis time was determined by a clot solubility test in 5M urea. � Results Fibrinogen concentration precipitated with protamin sulfate was measured as being 73 ± 8 mg/ml. The recovery of fibrinogen in cryoprecipitate was 93%. Thrombin mixed with fibrinogen had clot time of less than 5 seconds. Tensile strength and adhesion strength of fibrin sealant were 60 ± 8.9 g/cm2 and 55 ± 9 g, respectively. The average activity of the thrombin produced manually was 59.6 ± 6.2. Adding anti-fibrinolttic agent to fibrinogen concentrate has no effect on clotting time and tensile strength but it causes the stability improvement of fibrin clot. Conclusions Fibrinogen and thrombin prepared in this experiment have appropriate properties for production of fibrin sealants. Key words : Fibrin sealant, Fibrinogen, Thrombin, Plasma�
Dr. P. Eshghi, Dr. A. Cheraghali,
Volume 6, Issue 4 (Winter 2010)
Abstract
Abstract Background and Objectives Reports concerning serious illnesses caused by transfusion transmitted infections (TTI) in 1980s have caused numerous legal, social and economic consequences both for the patients and the societies. As a result, several lawsuits against authorities in the government and industry have been filled by the patients or advocacy groups. In Iran in 1990s such lawsuit was started against authorities of national blood transfusion organization. In this paper, comparative consequences of theses lawsuits have been evaluated. Materials and Methods Main databases such as Pubmed and ISI Web of Science have been searched for any such reports in both developing and developed countries in the past three decades. Results Although prevalence of TTI (e.g. AIDS and hepatitis C) in Iranian patients was substantially lower compared to the data reported in developed countries, compensation paid to the patients, as percent of GDP per capita, was significantly higher. Similar discrepancy was also observed in extension of the compensation and verdicts against national authorities that was much severer. Iran was the only country which had to provide in addition to substantial compensation free comprehensive treatment for the patients in extra to the existing national insurance system. As a result of such lawsuits, Iran has closed its only national plasma fractionation plant and after that it had to rely only on imported plasma products to meet the patients’ need. Conclusions Comparison of consequences of TTI in Iran with those of developed countries indicates a clear imbalance between the event and its consequences. This obviously has caused a clear unfair shift of the country’s health system privileges toward TTI contracted patients. On the other hand this unfair verdict against national authorities has ignored concepts of failure and fault in medical interventions. Key words : Transfusion-Transmitted Virus, Hemophilia, Blood Transfusion, Iran
M. Zahedpanah, Dr. A. Azarkeivan, Dr. B. Hajibeigi, Dr. M. Ahmadinezhad, Dr. P. Eshghi, Dr. M.r. Tabatabaiee, Dr. M. Maghsudlu,
Volume 7, Issue 2 (Summer 2010)
Abstract
Abstract
Background and Objectives
Thalassemia is a hereditary anemia requiring lifelong transfusion treatment with thromboembolism as one of its side effects. In the present study, we tried to determine the activity of anticoagulant proteins in thalassemic patients.
Materials and Methods
This descriptive study was conducted in Adult Thalassemia Clinic in Tehran. Measurement of protein C, S, and anti thrombin III levels were done. At the same time, we did these tests on 110 normal people who were matched by age and sex as the control group. The data were analyzed with Chi-Square, Pearson and T-test by SPSS 16.
Results
Out of 127 patients with the mean age of 29.4 year (SD ± 10.6), 114 (89.8%) were spelenectomized. Seven patients (5.5%) had history of thrombosis with 2 of them being diagnosed as major and 5 intermedia all of them were spelenectomized. In 61.1%, 67%, and 22.5% of thalassemic patients, the levels of protein C, protein S, and anti thrombin III decreased, respectively. We did not observe any correlation between these results and the type of thalassemia except antithrombin III (p= 0.001).
Conclusions
In our study, we observed significant decreased activity of protein C, S, and antithrombin III in comparison to the normal population which shows that thalassemic patients are prone to the thromboembolic events.
Key words: Thrombophilia, Thalassemia, Protein C, Protein S, Antithrombin III
Dr. P. Eshghi, Dr. A. Amin Asnafi,
Volume 8, Issue 2 (Summer 2011)
Abstract
Cerebral venous thrombosis in a child with Acute Lymphoblastic Leukemia and G20210A mutation of prothrombine gene during treatment Eshghi P.1, Amin Asnafi A.1 1 Shahid Beheshti University of Medical Sciences,Tehran,Iran Abstract Background and Objectives Cerebral vein thrombosis is a relatively rare but important complication during treatment of Acute Lymphoblastic Leukemia(ALL) in children. Case A 12 year old boy with pre-B ALL during the consolidation phase of treatment with BFM protocol was admitted with severe headache imaging study showed cerebral venous thrombosis in left sigmoid and lateral sinuses. Diagnostic evaluation revealed heterozygot mutation in G20210A prothombin gene. Conclusions Some hereditary hypercoagulability states such as prothrombin G20210A heterogeneity, play an important role in childhood thrombotic events during treatment of hematologic malignancy with medications such as L-asparginase. So venous thrombosis prophylaxis in this situation should be considered. Key words : Leukemia, Venous Thrombosis, Mutation, Prothrombin Sci J Iran Blood Transfus Org 2011 8(2): 143-148
Dr. E. Miri-Moghaddam, Dr. P. Eshghi, Dr. E. Sanei Moghaddam, Dr. Sm. Hashemi,
Volume 9, Issue 4 (Winter 2013)
Abstract
Abstract Background and Objectives Hemoglobinopathies are the most common single-gene disorders in Iran. Sistan and Balouchistan has 2300 hemoglobinopathy patients who judiciously receive blood in the southeast of Iran. In this study, the prevalence rate of hemoglobinopathies was evaluated in the province. Materials and Methods This descriptive analytical study was performed on 2129 people at the age range of 5-10 years who were selected by multistage cluster sampling method. The number of samples in each city was proportional to its population size. Hematologic parameters were evaluated by automated cell counter on EDTA whole blood, hemoglobin A2 (HbA2) was determined by column chromatography, and hemoglobins were separated on Acetate Cellulose at pH= 8.6. The samples with abnormal hemoglobins underwent electrophoresis at pH= 6.1. Results The results indicated 9 . 7% affected with minor thalassemia, with the frequency being variable between 6.2% in north cities to 12.9% in south cities of the province. A total of 0.9, 1.7 and 0.1% were heterozygous for hemoglobin S, D, and C, respectively. HbA2 level of 72.4% of heterozygous hemoglobinopathies was estimated to be within the range of healthy individuals. Conclusions The prevalence rate of β-thalassemia gene in the southern region of the province was higher than the average national rate. Current pre-marriage screening protocol is not able to identify all hemoglobinopathies in heterozygous cases. It is recommended where hemoglobinopathies are common, hemoglobin S detection be included in the screening program.
Dr. M. Naderi, Dr. M. Imani, Dr. P. Eshghi, A, Dorgalaleh, Sh. Tabibian, Dr. Sh. Alizadeh, Dr. E. Sanei Moghaddam, Dr. E. Miri-Moghaddam,
Volume 10, Issue 3 (Autumn 2013)
Abstract
Abstract Background and Objectives Factor XIII deficiency is one of the rarest bleeding disorders with an estimated prevalence of 1 in 1-3 million in the general population. The main clinical manifestations of the disease are delayed wound bleeding, recurrent miscarriage, intracranial bleeding, and umbilical cord bleeding. The prevalence of the disease in the regions such as Sistan and Baluchistan with consanguinity marriages is higher. The aim of this study was to assess the diagnosis and treatment of factor XIII deficiency in Sistan and Baluchistan province. Materials and Methods This descriptive study was performed on 205 patients with the severe factor XIII deficiency. The diagnosis of the disease was done by a wide spectrum of characteristics including family history, clinical manifestations, laboratory tests, clot solubility in 5 M urea or monochloroacetic acid 1% environments. Results It seems that Khash city has the highest prevalence of the disease worldwide. The molecular analysis of the patients showed that an identical homozygote mutation TGG —› CGG at codon 187 in exon 4 of catalytic A subunit is responsible of this deficiency. The common manifestations of the disease at time of diagnosis were umbilical bleeding (84.4%), deep soft tissue haematoma (54.4%), and less frequently gum bleeding and finally ecchymosis. Conclusions It seems that Sistan and Baluchistan province has the highest prevalence of factor XIII deficiency worldwide with a dramatic increase of 46 cases in 2008 to 205 patients in 2012 that alarmed the absence of a screening test in this region.
Dr Mohammad Thaghi Arzanian, Dr. B.sh. Shamsian, Dr. P. Eshghi, Dr. M. Kajiyazdi, Dr. S. Alavi, Dr. Sh. Nazari, Dr. K. Goudarziour,
Volume 12, Issue 1 (Spring 2015)
Abstract
Abstract Background and Objectives The use of vascular access devices (VADs) is an integral aspect of health care for neonates, children, and adults and has moved beyond the acute care setting to chronic, long-term care. VADs have a paramount role throughout the management of the oncology patient, as they are needed in the initial phases for surgery or chemotherapy, in the advanced stages for chronic treatment, and in the last stages for palliative measures. In patients with cancer, chemotherapeutic drugs can damage the wall of peripheral veins thereby rapidly putting an end to the peripheral access. Central venous lines (CVLs) were first described by Dudrick in 1968. In 1973, the first long-term central venous catheter (CVC) was used for parenteral nutrition. In 1979, the Hickman catheter, a long-term venous access device, was used for chemotherapy for the first time. The introduction of totally implantable port systems started in the early 1980s. In this article, we will review the use of port A Cath and its role in hematology-oncology patients based on the literature review. Materials and Methods This article was provided based of review of many recent anf up-to-date articles in field of port A Cath uding and its role in hematology-oncology patients. Results Evaluation these articles showed the essential role of port A Cath and the best ways to deal with the possible complications. Conclusions Review of articles revealed the essential role of port A Cath in hematology-oncology patients. Also it is necessary to be careful about using and care of port A Cath.
Dr. N. Dehghan Nayeri, Dr. P. Eshghi, Dr. K. Goudarzi Pour, M. Darvishi, Dr. َ. Gharehbaghian,
Volume 15, Issue 2 (Summer 2018)
Abstract
Abstract
Background and Objectives
ALL is the most common malignancy in childhood. Presently, approximately 20% of patients do not respond to treatment due to the resistance of leukemia blasts. Response to GCs is considered as the strongest independent factor in predicting ALL patients outcome. Therefore, identification of GCs resistance markers are the beneficial tools for improvement of prognostic strategies in ALL.
Materials and Methods
In this experimental study, the protein-protein interaction network of fourteen significant down or up-regulated proteins in the proteome of human lymphoblastic cell treated with prednisolone and dexamethasone were analyzed by using the STRING online database.
Results
By using proteomics methods, fourteen down or up-regulated proteins, SRSF3, CNBP, VDAC1, SNX3, PFDN6, PSMB2, STMN1, PPP4R4, DUT, CAPZA1, CAPZB, PNP, CLIC1 and PSME1 were recognized in both the sensitive and resistant GC cell lines. Correlation between these proteins were analyzed by using the STRING database.
Conclusions
Overall, the findings showed that the Ubiquitin-Proteasome pathway plays a pivotal role in inducing resistance to GC in ALL. Therefore, the study of key controlling proteins in this pathway can play an important role in clarifying the mechanisms of induction of resistance to GC and consequently the prognosis of the disease.
|
|
.jpg)
.png)
